Clinical Trials Logo

Cystic Fibrosis clinical trials

View clinical trials related to Cystic Fibrosis.

Filter by:

NCT ID: NCT06313827 Not yet recruiting - Cystic Fibrosis Clinical Trials

e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population

Start date: March 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to analyse the impact of a telematic assessment and monitoring protocol in people with cystic fibrosis, in order to identify exacerbations early, thus preventing loss of lung function and maintaining quality of life. Participants will be assigned to one of 3 study groups: Control group (CG-1): will receive their usual physiotherapy treatment; Treatment group (TG-2): will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment; Treatment and follow-up group (TGF-3): will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment, plus telematic control of exacerbations with feedback from the physiotherapist.

NCT ID: NCT06312787 Not yet recruiting - Cystic Fibrosis Clinical Trials

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Start date: March 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the relative bioavailability, effect of food on the pharmacokinetic parameters, and safety and tolerability, of a tablet formulation of VX-118 in healthy participants.

NCT ID: NCT06311292 Not yet recruiting - Cystic Fibrosis Clinical Trials

Intrapulmonary Percussive Ventilation for Sputum Induction in Adults With Cystic Fibrosis

Start date: March 2024
Phase: N/A
Study type: Interventional

This is a small pilot study with the goal of identifying a superior sputum collection method in Cystic Fibrosis patients unable to produce a sputum. Participants will use the Volera MetaNeb System during clinic visit in an attempt to produce sputum.

NCT ID: NCT06306508 Recruiting - Cystic Fibrosis Clinical Trials

Effect of Parental Attitude on Functional and Physical Level of Children With Cystic Fibrosis

Start date: February 16, 2024
Phase:
Study type: Observational [Patient Registry]

Some parents may be more protective of children with CF due to concerns about worsening of the disease due to infection, which can affect their functional level. The goal of this observational study is to learn about the family's protective approach to the functioning and disease course of children with cystic fibrosis (CF) to determine whether there are possible negative effects. There will be an alternative viewpoint offered to clinicians regarding the management of CF with outputs of this study.

NCT ID: NCT06302270 Recruiting - Cystic Fibrosis Clinical Trials

CFTR Modulators in Pregnancy and Postpartum

Start date: March 15, 2024
Phase:
Study type: Observational

Observational study on women with Cystic Fibrosis treated with CFTR modulators during pregnancy and postpartum and their children. Registration on maternal health parameters and effects of CFTR-modulators in the newborn infant as well as effects of exposure through mother's own milk.

NCT ID: NCT06300567 Not yet recruiting - CFTR-RD Clinical Trials

Assessment of Patients Not Concluded After Neonatal Screening of Cystic Fibrosis.

Start date: May 1, 2024
Phase:
Study type: Observational

Assessment of the outcome of patients not concluded fir cystic fibrosis, either symptomatic patients or asymptomatic children detected by newborn screening for cystic fibrosis. The aim is to identify patients potentially at risk of progressing to the clinical spectrum of cystic fibrosis

NCT ID: NCT06299709 Not yet recruiting - Cystic Fibrosis Clinical Trials

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Start date: March 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the relative bioavailability, food effect, and dose proportionality of a granule formulation of VNZ/TEZ/D-IVA.

NCT ID: NCT06299696 Not yet recruiting - Cystic Fibrosis Clinical Trials

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Start date: March 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the flavor (basic tastes, aroma, texture, mouthfeel) of VNZ/TEZ/D-IVA fixed dose combination (FDC) granules.

NCT ID: NCT06299566 Completed - Cystic Fibrosis Clinical Trials

Perceptions of the CF Screening Protocol Incorporating NGS

Start date: January 19, 2022
Phase:
Study type: Observational

Newborn bloodspot screening (from now on referred to as screening) for cystic fibrosis (CF) became part of the national screening programme in 2007. Screening for CF is also well established internationally. The current process works well but has some disadvantages: carrier reporting - which is not the intention of CF screening in the UK (~200 pa); need for repeat samples which can be costly and contribute to parental worry (~300 pa.); mutation panels not fully reflecting the ethnic diversity of the birth population; identification of children designated as CF screen positive, inconclusive diagnosis (CFSPID) which can cause uncertainty (~20-30 pa). A trial of NGS in one centre in the UK, for one year found that it was technically feasible at reasonable cost and with an acceptable turn around time. In addition, the trial determined that using NGS could mitigate against some of the disadvantages described above. The purpose of this piece of work was to: 1. Gather, compare and analyse the views of a range of stakeholders on the proposed CF screening protocol incorporating NGS. 2. Use the outcomes to inform discussions and decisions by the fetal, maternal and child health (FMCH) group and UK National Screening Committee (NSC) about the proposed protocol 3. Consider what generalisable information on the views of stakeholders on newborn screening could be generated from this exercise to inform other FMCH and UK NSC discussions 4. Evaluate and learn from the exercise to inform future stakeholder engagement activities by the UK NSC and screening programmes.

NCT ID: NCT06296394 Not yet recruiting - Cystic Fibrosis Clinical Trials

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

HOPeCF
Start date: March 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators. The investigators will collect physical and mental health data to comprehensively evaluate the impact of parenthood in CF with widespread highly effective CFTR modulator use. The main hypotheses this study aims to examine are: H1: Parents with CF and moderate-to-severe depression have more rapid change in ppFEV1 (percent predicted forced expiratory volume in one second) versus those with mild or no depression. H2: Parents with CF who have more parental responsibility and/or stress have more rapid ppFEV1 (percent predicted forced expiratory volume in one second) change than those with less responsibility/stress H3: Parents using CFTR modulators have decreased ppFEV1 (percent predicted forced expiratory volume in one second) change versus those not using CFTR modulators Participants will complete quarterly surveys during the first year of parenthood and biannual surveys, thereafter, using the computer-based survey system on an iPad protected for infection control or via personal device or computer via emailed survey link.